| Q73093126 | 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group |
| Q33925505 | 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development |
| Q28362939 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer |
| Q44746726 | 5-fluorouracil-induced coronary vasospasm |
| Q77713974 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer |
| Q37341713 | A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer |
| Q37234171 | A phase II study of leucovorin, 5-FU and docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer |
| Q48750119 | A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. |
| Q36615696 | Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. |
| Q36317002 | Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. |
| Q41180643 | Alteration of Drug Sensitivity in Human Colon Cancer Cells after Exposure to Heat: Implications for Liver Metastasis Therapy using RFA and Chemotherapy. |
| Q33363615 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin |
| Q39342071 | Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil |
| Q33417225 | Antineoplastic agents and the associated myelosuppressive effects: a review |
| Q36616217 | Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines |
| Q33432892 | Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency |
| Q36106736 | Benefit-risk assessment of irinotecan in advanced colorectal cancer |
| Q38200600 | Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance |
| Q36608809 | Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy |
| Q77128658 | Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group |
| Q41056508 | Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line |
| Q64273134 | Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil |
| Q41856934 | Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa |
| Q37449224 | Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer |
| Q44181002 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. |
| Q34666588 | Coronary vasospasm secondary to 5-Fluorouracil and its management: case report |
| Q35097713 | Curative treatment of gastric cancer: towards a multidisciplinary approach? |
| Q37602208 | DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. |
| Q37450200 | DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy |
| Q41741368 | Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? |
| Q54035916 | Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. |
| Q34216563 | Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity |
| Q33711597 | Does biomodulation of 5-fluorouracil improve results? |
| Q73356010 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients |
| Q33706220 | Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. |
| Q35097975 | Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer |
| Q34847802 | Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? |
| Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
| Q40275457 | Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. |
| Q35048269 | Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer |
| Q86167560 | Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability |
| Q40361727 | In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line |
| Q46844116 | In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting |
| Q41897991 | Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase |
| Q42619097 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. |
| Q58033437 | Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge |
| Q33706287 | Is there a standard chemotherapeutic strategy in colorectal cancer? |
| Q46765481 | Looking for the right drug for the right patient: a tale of old drugs and new pathways |
| Q43211296 | MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches |
| Q43296440 | MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis |
| Q52170109 | Mechanisms of Action and Modulation of Fluorouracil. |
| Q37975508 | Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status |
| Q36216117 | Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer |
| Q36291281 | New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). |
| Q33875868 | New directions in the treatment of colorectal cancer: a look to the future |
| Q40845274 | New drugs in the treatment of colorectal carcinoma |
| Q43153295 | Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. |
| Q35111182 | Palliative Treatment of Patients with Colorectal Cancer |
| Q36989058 | Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older |
| Q35755386 | Pancreatic cancer and FOLFIRINOX: a new era and new questions |
| Q43871119 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer |
| Q42178970 | PharmGKB summary: fluoropyrimidine pathways |
| Q30300958 | Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation |
| Q37235638 | Pharmacogenetics in colorectal cancer: a systematic review |
| Q73269127 | Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies |
| Q47593467 | Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study |
| Q36619756 | Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance |
| Q28544740 | Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients |
| Q37228492 | Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer |
| Q34754672 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. |
| Q39162488 | Re-evaluation of cellular radiosensitization by 5-fluorouracil: high-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration |
| Q36114988 | Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer |
| Q55154822 | Relevance of MTHFR polymorphisms with response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer: a meta-analysis. |
| Q54117544 | Resistance to 5-fluorouracil. |
| Q42820147 | Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q73355992 | Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers |
| Q36294882 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study |
| Q43191517 | Second-line therapy for advanced colorectal cancer. |
| Q40832181 | Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer |
| Q92669417 | Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer |
| Q38204673 | Standing the test of time: targeting thymidylate biosynthesis in cancer therapy |
| Q37694213 | Synchronous ovarian carcinoma with colorectal metastases: an unusual presentation |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q95406754 | TAS-102 in refractory colorectal cancer: caution is needed |
| Q38149290 | Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed |
| Q36090448 | The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q34761260 | The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil |
| Q36291294 | The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer |
| Q36322069 | The glutamatergic system outside the CNS and in cancer biology |
| Q74754732 | The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK) |
| Q35862225 | Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review |
| Q52187605 | Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. |
| Q77668171 | Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen |
| Q34497992 | Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide |
| Q33566877 | Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer |
| Q35585759 | Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase |
| Q73869659 | [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)] |